US 11351120
Use of higher doses of modified release huperzine formulations
granted A61KA61K31/439A61K31/4748
Quick answer
US patent 11351120 (Use of higher doses of modified release huperzine formulations) held by Supernus Pharmaceuticals, Inc. expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Supernus Pharmaceuticals, Inc.
- Grant date
- Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K31/439, A61K31/4748, A61K9/1676, A61K9/5042